Form 8-K Filing Regarding Nasdaq Listing Standards

Bone Biologics Corporation received a notification from Nasdaq on September 10, 2026, indicating that the company no longer meets the minimum bid price requirement of $1 per share, as the closing bid price has been below this threshold for 30 consecutive business days. The company has a compliance period of 180 days, until March 9, 2027, to regain compliance. This can be achieved by demonstrating a closing bid price of at least $1 per share for 10 consecutive business days. If compliance is not met, the company may be eligible for a second 180-day period if it meets other listing requirements. Nasdaq will issue a delisting notice if compliance is not achieved, with an option to appeal. The company plans to monitor its stock price and consider a reverse stock split, subject to stockholder approval, to increase the per-share price and meet Nasdaq's continued listing standards. The notification does not immediately affect the stock's listing.